Jefferies Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall Street rallies, Dow closes at record on Iran talks optimism
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
TD Cowen: 'We view yesterday's announcement as highly positive for PRAX'
December 31, 2025 7:16 AM ESTTD Cowen analyst Ritu Baral reiterated a Buy rating and $353.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).
The analyst comments "Yesterday AM, PRAX announced it was granted Breakthrough Designation (BTD) for ulixa in Essential Tremor (ET). As a reminder, per the FDA website, BTD is a process designed to expedite the development and review of drugs... More
